Table 3. Pathological and clinical characteristics of mCRC patients.
| Characteristics | No. of patients | % |
| Age (years) | ||
| Median (range) | 66 (28–85) | |
| Gender | ||
| Female | 9 | 29.0 |
| Male | 22 | 71.0 |
| Primary tumor site | ||
| Right colon | 12 | 38.7 |
| Left colon | 18 | 58.1 |
| Unknown | 1 | 3.2 |
| Tumor | ||
| T2 | 2 | 6.5 |
| T3 | 18 | 58.1 |
| T4 | 3 | 9.7 |
| Tx | 8 | 25.8 |
| Nodal | ||
| N0 | 5 | 16.1 |
| N1 | 4 | 12.9 |
| N2 | 12 | 38.7 |
| N3 | 1 | 3.2 |
| Nx | 9 | 29.0 |
| Lymphovascular invasion | ||
| Yes | 15 | 48.4 |
| No | 16 | 51.6 |
| Tumor grade | ||
| Low/Moderate | 20 | 64.5 |
| High | 11 | 35.5 |
| Adjuvant therapy | ||
| Yes | 5 | 16.1 |
| No | 26 | 83.9 |
| 1st line regimens | ||
| Folfiri plus Bevacizumab | 17 | 56.7 |
| Folfox plus Bevacizumab | 9 | 30.0 |
| Folfiri plus Panitumumab | 1 | 3.4 |
| Folfox plus Panitumumab | 1 | 3.4 |
| Folfiri | 1 | 3.4 |
| Folfox | 1 | 3.4 |